Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

NCT03326752 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non Small Cell Lung Cancer

Interventions

DRUG: DV281
DEVICE: Breath Actuated Nebulizer
DRUG: DV281 (RP2D)
DRUG: Approved Anti-PD-1 Inhibitor

Sponsor

Dynavax Technologies Corporation